key: cord-0773289-5akdcymb authors: Petersen, Eskild; Lucey, Daniel; Blumberg, Lucille; Kramer, Laura D.; Al-Abri, Seif; Lee, Shui Shan; de Castro Abreu Pinto, Tatiana; Obiero, Christina W.; Rodriguez-Morales, Alfonso J.; Yapi, Richard; Abubakar, Aisha; Tambyah, Paul Anantharajah; Holmes, Allison; Chen, Lin H. title: Answer to Paredes et al. commenting on “COVID-19 vaccines under the International Health Regulations - We must use the WHO International Certificate of Vaccination or Prophylaxis” date: 2021-02-24 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.076 sha: 0e04fcf9657dd36c9d63cbb1e63ce7e919b8cf7f doc_id: 773289 cord_uid: 5akdcymb nan We would argue that under the IHR those with proven immunity (positive serology) or verified immunization should be exempted from travel restrictions no matter which part of the world they come from, thereby enabling the gradual and safe reopening of society. Dr Paredes at al. question whether immunity is long lived. It is true that we have limited information on long term immunity. However, a conservative estimate as we propose in our editorial could be six months and we need to be practical so proven immunity can be operational. Perhaps a proportion may lose protective immunity earlier but at least it would allow travel with very limited risk of transmission. In one study N and S specific IgG antibody titres were found to remain stable for at least 4 months post-diagnosis [Wajnberg et al. 2020] . A recent review concludes that "Overall, the evidence from observational studies in both SARS-CoV and SARS-CoV-2 infection, along with the promising data from clinical trials across 42 vaccine candidates, provide sufficient reason to speculate that a vaccine for SARSCoV-2 will be safe and could provide lasting protective immunity that even if not lifelong might persist for years" [Kim et al. 2020 ]. Another study found that virus-reactive memory B cells suggesting that even if antibody levels wane, longlived MBCs remain to mediate rapid antibody production [Nguyen-Contant et al. 2020] . A J o u r n a l P r e -p r o o f study of T-cell immunity to SARS-CoV found reactive T cells 17 years after the infection [Le Bert et al. 2020] In conclusion we believe that travel and reopening of businesses and cultural activities will be facilitated when people can clearly demonstrate documentation of immunity whether natural or after immunization. Health equity is an important separate issue which is not handled through the IHR, but rather by other organizations for which we agree need support and encouragement. COVID-19 vaccines under the International Health Regulations -We must use the WHO International Certificate of Vaccination or Prophylaxis Directorate General for Disease Surveillance and Control, Ministry of Health, Oman 11. JC School of Public Health and Primary Care, The Chinese University of Hong Kong Working for global equitable access to COVID-19 vaccines Will SARS-CoV-2 Infection Elicit LongLasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.mBio COVID-19 vaccines under the International Health Regulations -We must use the WHO International Certificate of Vaccination or Prophylaxis Robust neutralizing antibodies to SARS-CoV-2 infection persist for months No conflict of interest to declare. None. Approval was not required.